In a CAR-T therapy trial for lung cancer patients, CAR-T therapy was able to effectively recognize and kill tumor cells with insufficient MHC I expression, compensating for the limitations of traditional T cells that rely on MHC recognition (97, 98). This evidence concerns the gene HLA-C and neoplasm.